COIOSDeep risk insights through multi-disciplinary research across the globe
a room filled with lots of shelves filled with boxes and boxes
Item new Peer-reviewed Added

GLP-1 receptor agonists obtained direct-to-consumer and compounded use in a US survey

Among US adults using GLP-1 receptor agonists, 73.0% buying direct-to-consumer reported compounded products, against 12.9% using clinicians or pharmacies.

This study examined where US adults obtain GLP-1 receptor agonists and how the source relates to compounded use and nonadherence. Data came from a National Center for Health Statistics survey of 8,118 adults in July and August 2025. Past-year use was reported by 9.8% of adults, about 25.9 million, and 18.3% of users bought direct-to-consumer. Direct-to-consumer buying was linked to compounded use (adjusted odds ratio, aOR, 14.56) and insurance nonpayment (aOR 8.01). It was also linked to cost-attributed nonadherence (aOR 4.94), but not significantly to supply-attributed nonadherence. The design is cross-sectional and self-reported, so it cannot show that acquisition channel causes these outcomes.

Why it is interesting: About one in five users bought direct-to-consumer, and 73.0% of these who knew the product status reported compounded drugs. Buying this way was linked to cost-attributed nonadherence, while the supply-attributed association was not statistically significant.

Source
American Journal of Health-System Pharmacy, 20 November 2026
Paper
Where patients obtain GLP-1 receptor agonists: direct-to-consumer channels, compounded product use, and reason-specific nonadherence in a national survey
Authors
Bhagavathula AS, Abegaz TM
DOI
10.1093/ajhp/zxag415
Type
Peer-reviewed article
Design
Cross-sectional survey-weighted analysis, NCHS Rapid Surveys System Round 7 (July–August 2025), N=8,118 adults, 976 past-year GLP-1 users
Verdict
New finding
Driver
Obesity, diabetes and GLP-1
Abstract — the authors' own words, CC BY

To examine acquisition channels for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and associations with compounded use, prescription status, and nonadherence. This cross-sectional analysis used the National Center for Health Statistics Rapid Surveys System Round 7 (July-August 2025; N = 8118). Among 976 past-year users, channels were classified as clinician/pharmacy without direct-to-consumer (DTC) acquisition, any DTC telehealth/medical spa, or other. Survey-weighted logistic regression estimated adjusted odds ratios (aORs). GLP-1 RA use was reported by 9.8% of adults, approximately 25.9 million. Of users, 18.3% used a DTC or medical spa channel and 9.2% reported no clinician prescription. Among users reporting known compounded status, compounded use was 73.0% (95% CI, 62.7%-81.2%) for DTC versus 12.9% (8.8%-18.4%) for conventional acquisition (aOR, 14.56; 95% CI, 7.99-26.54). Overall, 22.6% reported compounded use and 8.6% did not know. DTC acquisition was associated with cost-attributed nonadherence (aOR, 4.94; 95% CI, 2.77-8.81); the supply-attributed association was not statistically significant (aOR, 1.15; 95% CI, 0.56-2.38; contrast P < 0.001). Associations were also observed for side-effect-attributed reduction/discontinuation (aOR, 2.12; 95% CI, 1.05-4.27) and complete discontinuation (aOR, 1.83; 95% CI, 1.01-3.32). Counseling associations were imprecise. Insurance nonpayment was associated with DTC acquisition (aOR, 8.01; 95% CI, 4.70-13.67). DTC acquisition was associated with compounded use, insurance nonpayment, and cost-attributed nonadherence. These cross-sectional findings suggest that acquisition sources and reasons for nonadherence may be useful topics for patient assessment. They do not establish causal effects of acquisition channel or demonstrate that medication records are incomplete.

Other drivers in Health today